论文部分内容阅读
为探讨我国成人急性淋巴细胞白血病(A-ALL)的有效治疗方案,提高我国A-ALL的疗效,设计了一个早期连续4个疗程无交叉耐药强化巩固治疗后再行自体骨髓移植(ABMT)治疗A-ALL的方案。共有30例A-ALL患者(中位年龄27岁)进入该方案的治疗观察,已有20例完成全程治疗。结果:本方案的毒性可以耐受,近期疗效较好,ABMT后中位随访时间28(4~70)个月,3年无病生存率为68.5%±10.5%,复发率30.8%±12.5%。本资料初步表明,A-ALL在取得CR后早期进行较充分的强化巩固治疗后再行ABMT可以获得较好的疗效。本方案是治疗A-ALL的一个有效方案,值得推广。
To investigate the effective treatment of adult acute lymphoblastic leukemia (A-ALL) in China and improve the efficacy of A-ALL in China, we designed an early four consecutive courses of treatment without cross-resistance, strengthening and consolidation, followed by autologous bone marrow transplantation (ABMT). Treatment of A-ALL program. A total of 30 patients with A-ALL (median age 27 years old) entered the treatment of this program, and 20 patients have completed the whole course of treatment. RESULTS: The toxicity of this regimen was tolerable with good short-term efficacy. The median follow-up time after ABMT was 28 (4 to 70) months, the 3-year disease-free survival rate was 68.5% ± 10.5%, and the recurrence rate was 30. .8%±12.5%. This data indicates initially that A-ALL can be treated with ABMT in the early stage after obtaining adequate reinforcement and consolidating treatment. This program is an effective treatment for A-ALL and worthy of promotion.